Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Immunovant (IMVT) Enterprise Value (2018 - 2026)

Immunovant filings provide 8 years of Enterprise Value readings, the most recent being -$994.5 million for Q4 2025.

  • Quarterly Enterprise Value fell 165.42% to -$994.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$994.5 million through Dec 2025, down 165.42% year-over-year, with the annual reading at -$714.0 million for FY2025, 12.37% down from the prior year.
  • Enterprise Value hit -$994.5 million in Q4 2025 for Immunovant, down from -$521.9 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$269.9 million in Q3 2023 and bottomed at -$994.5 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$513.9 million, with a median of -$493.8 million recorded in 2022.
  • The largest annual shift saw Enterprise Value surged 45.77% in 2024 before it plummeted 165.42% in 2025.
  • Immunovant's Enterprise Value stood at -$527.0 million in 2021, then rose by 17.91% to -$432.6 million in 2022, then crashed by 59.72% to -$690.9 million in 2023, then surged by 45.77% to -$374.7 million in 2024, then plummeted by 165.42% to -$994.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Enterprise Value are -$994.5 million (Q4 2025), -$521.9 million (Q3 2025), and -$598.9 million (Q2 2025).